
|Slideshows|June 28, 2018
ADA 2018: CV Benefits of SGLT-2 Inhibitors
Author(s)Kenneth J. Bender, PharmD, MA
Three studies at ADA 2018 highlight the current track record of SGLT-2is in reducing CV-related morbidity and mortality.
Advertisement
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
New Menopause Survey Finds Energy Loss, Poor Sleep, and Seasonal Symptoms Most Disruptive
2
The Adult Immunization Catch-Up Schedule: A Practical Guide for Primary Care
3
The Menopause Society 2025 Annual Meeting: A Primary Care Preview
4
Identifying and Managing Vascular Disease in Primary Care: A Q&A With Family Physician Kabiul Haque, MD
5